Loading...
XNASRARE
Market cap4.03bUSD
Jan 08, Last price  
43.65USD
1D
-1.78%
1Q
-18.97%
Jan 2017
-37.92%
IPO
11.92%
Name

Ultragenyx Pharmaceutical Inc

Chart & Performance

D1W1MN
XNAS:RARE chart
P/E
—
P/S
9.28
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.12%
Rev. gr., 5y
53.18%
Revenues
434m
+19.52%
00000133,0002,612,00051,495,000103,714,000271,030,000351,406,000363,329,000434,249,000
Net income
-607m
L-14.25%
-6,849,000-16,334,000-35,070,000-59,802,000-145,618,000-245,874,000-302,139,000-197,611,000-402,727,000-186,566,000-454,025,000-707,421,000-606,639,000
CFO
-475m
L+24.80%
-5,825,000-12,504,000-31,200,000-44,634,000-105,977,000-160,975,000-253,843,000-290,566,000-345,383,000-132,220,000-338,695,000-380,465,000-474,806,000
Earnings
Feb 13, 2025

Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
URL
https://www.ultragenyx.com/
IPO date
Jan 31, 2014
Employees
1,311
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
434,249
19.52%
363,329
3.39%
Cost of revenue
693,658
734,109
Unusual Expense (Income)
NOPBT
(259,409)
(370,780)
NOPBT Margin
Operating Taxes
(1,825)
5,696
Tax Rate
NOPAT
(257,584)
(376,476)
Net income
(606,639)
-14.25%
(707,421)
55.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
379,755
10,813
BB yield
-10.80%
-0.33%
Debt
Debt current
12,595
11,779
Long-term debt
73,743
51,407
Deferred revenue
Other long-term liabilities
874,530
880,259
Net debt
(690,772)
(988,047)
Cash flow
Cash from operating activities
(474,806)
(380,465)
CAPEX
(44,267)
(146,123)
Cash from investing activities
168,000
(291,652)
Cash from financing activities
388,142
501,208
FCF
(262,463)
(485,980)
Balance
Cash
577,209
896,732
Long term investments
199,901
154,501
Excess cash
755,398
1,033,067
Stockholders' equity
(3,386,932)
(2,787,525)
Invested Capital
4,580,045
4,051,871
ROIC
ROCE
EV
Common stock shares outstanding
73,544
69,914
Price
47.82
3.22%
46.33
-44.90%
Market cap
3,516,867
8.57%
3,239,126
-43.18%
EV
2,826,095
2,251,079
EBITDA
(233,403)
(352,560)
EV/EBITDA
Interest
66,004
43,015
Interest/NOPBT